Remo Guerrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6041571/publications.pdf

Version: 2024-02-01

259 papers

10,013 citations

51 h-index 84 g-index

261 all docs

261 docs citations

times ranked

261

6662 citing authors

#	Article	IF	CITATIONS
1	Fluorescent opioid receptor ligands as tools to study opioid receptor function. Journal of Pharmacological and Toxicological Methods, 2022, 113, 107132.	0.7	2
2	Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. Frontiers in Pharmacology, 2022, 13, 873082.	3.5	3
3	The N-terminal domain of Helicobacter pylori's Hpn protein: The role of multiple histidine residues. Journal of Inorganic Biochemistry, 2021, 214, 111304.	3.5	8
4	Stress induces reinstatement of extinguished cocaine conditioned place preference by a sequential signaling via neuropeptide S, orexin, and endocannabinoid. Addiction Biology, 2021, 26, e12971.	2.6	8
5	Structure–Activity Relationship Studies on Oxazolo[3,4- <i>a</i>)]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent <i>In Vivo</i> Activity. Journal of Medicinal Chemistry, 2021, 64, 4089-4108.	6.4	5
6	Folic Acid–Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. Journal of Medicinal Chemistry, 2021, 64, 3204-3221.	6.4	13
7	Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines, 2021, 9, 526.	4.4	1
8	Novel Mixed NOP/Opioid Receptor Peptide Agonists. Journal of Medicinal Chemistry, 2021, 64, 6656-6669.	6.4	7
9	Neuropeptide S-initiated sequential cascade mediated by OX1, NK1, mGlu5 and CB1 receptors: a pivotal role in stress-induced analgesia. Journal of Biomedical Science, 2020, 27, 7.	7.0	15
10	Cu(II) coordination to His-containing linear peptides and related branched ones: Equalities and diversities. Journal of Inorganic Biochemistry, 2020, 205, 110980.	3.5	8
11	Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1–13)-NH ₂ . Journal of Medicinal Chemistry, 2020, 63, 10782-10795.	6.4	6
12	Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test. Behavioural Brain Research, 2019, 356, 120-126.	2.2	9
13	Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test. European Journal of Pharmacology, 2019, 859, 172557.	3.5	8
14	Bioinorganic chemistry of calcitermin – the picklock of its antimicrobial activity. Dalton Transactions, 2019, 48, 13740-13752.	3.3	17
15	Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. Bioconjugate Chemistry, 2019, 30, 2444-2451.	3.6	4
16	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. Molecules, 2019, 24, 3493.	3.8	4
17	Thermodynamic and spectroscopic study of Cu(⟨scp⟩ii⟨ scp⟩) and Zn(⟨scp⟩ii⟨ scp⟩) complexes with the (148–156) peptide fragment of C4YJH2, a putative metal transporter of⟨i⟩Candida albicans⟨ i⟩. Metallomics, 2019, 11, 1988-1998.	2.4	10
18	Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors. Peptides, 2018, 99, 195-204.	2.4	13

#	Article	IF	Citations
19	Central noradrenergic activity affects analgesic effect of Neuropeptide S. Journal of Anesthesia, 2018, 32, 48-53.	1.7	7
20	NOP-Targeted Peptide Ligands. Handbook of Experimental Pharmacology, 2018, 254, 17-36.	1.8	5
21	Nociceptin/Orphanin FQ and Urinary Bladder. Handbook of Experimental Pharmacology, 2018, 254, 347-365.	1.8	8
22	Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. Pharmacology Research and Perspectives, 2018, 6, e00445.	2.4	6
23	Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans. Frontiers in Molecular Biosciences, 2018, 5, 100.	3.5	11
24	NOP receptor pharmacological profile $\hat{a} \in A$ dynamic mass redistribution study. PLoS ONE, 2018, 13, e0203021.	2.5	15
25	Glycation affects fibril formation of $\hat{Al^2}$ peptides. Journal of Biological Chemistry, 2018, 293, 13100-13111.	3.4	47
26	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2018, 61, 7374-7380.	6.4	6
27	Design and Synthesis of 99mTcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection. Pharmaceuticals, 2018, 11, 70.	3.8	6
28	NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. Psychopharmacology, 2018, 235, 3093-3102.	3.1	21
29	Zn(II) and Ni(II) complexes with poly-histidyl peptides derived from a snake venom. Inorganica Chimica Acta, 2018, 472, 149-156.	2.4	12
30	Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor. Organic and Biomolecular Chemistry, 2017, 15, 4704-4710.	2.8	15
31	Effects of [Nphe ¹ , Arg ¹⁴ , Lys ¹⁵] N/OFQ-NH ₂ (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. Journal of Psychopharmacology, 2017, 31, 691-703.	4.0	25
32	A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism. Scientific Reports, 2017, 7, 2416.	3.3	8
33	Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands. Scientific Reports, 2017, 7, 45817.	3.3	6
34	Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13). European Journal of Pharmacology, 2017, 794, 115-126.	3.5	23
35	In vitro pharmacological characterization of a novel unbiased <scp>NOP</scp> receptorâ€selective nonpeptide agonist <scp>AT</scp> â€403. Pharmacology Research and Perspectives, 2017, 5, e00333.	2.4	22
36	Neuropeptide S receptor ligands: a patent review (2005-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 347-362.	5.0	12

#	Article	IF	Citations
37	Preferential interaction of the Alzheimer peptide Aβâ€(1–42) with Omegaâ€3â€containing lipid bilayers: structure and interaction studies. FEBS Letters, 2016, 590, 582-591.	2.8	10
38	Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacology Research and Perspectives, 2016, 4, e00247.	2.4	51
39	DOES hemopressin bind metal ions in vivo?. Dalton Transactions, 2016, 45, 18267-18280.	3.3	5
40	In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. European Journal of Pharmacology, 2016, 793, 1-13.	3.5	18
41	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. Scientific Reports, 2016, 6, 27198.	3.3	10
42	Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma. British Journal of Pharmacology, 2016, 173, 1286-1301.	5.4	25
43	Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. Psychopharmacology, 2016, 233, 2525-2532.	3.1	33
44	The unusual metal ion binding ability of histidyl tags and their mutated derivatives. Dalton Transactions, 2016, 45, 5629-5639.	3.3	26
45	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. Journal of Medicinal Chemistry, 2016, 59, 147-156.	6.4	22
46	Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). PLoS ONE, 2016, 11, e0156897.	2.5	26
47	In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. Pharmacology Research and Perspectives, 2015, 3, e00108.	2.4	9
48	Physicochemical stability of cabazitaxel and docetaxel solutions. European Journal of Hospital Pharmacy, 2015, 22, 150-155.	1.1	5
49	Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice. Peptides, 2015, 72, 95-103.	2.4	29
50	Structure activity studies of nociceptin/orphanin FQ($1\hat{a}$ e"13)-NH2 derivatives modified in position 5. Bioorganic and Medicinal Chemistry, 2015, 23, 1515-1520.	3.0	6
51	Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 33-41.	3.0	7
52	Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor. Neuropharmacology, 2015, 97, 1-6.	4.1	16
53	Nociceptin/orphanin FQ and stress regulate synaptophysin expression in the rat fundic and colonic mucosa. Tissue and Cell, 2015, 47, 147-151.	2.2	2
54	Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats. European Journal of Pharmacology, 2015, 754, 73-81.	3.5	18

#	Article	IF	Citations
55	Selective Breeding for High Anxiety Introduces a Synonymous SNP That Increases Neuropeptide S Receptor Activity. Journal of Neuroscience, 2015, 35, 4599-4613.	3.6	50
56	The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor. Structure, 2015, 23, 2291-2299.	3.3	64
57	Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. European Journal of Pharmacology, 2015, 766, 155-162.	3.5	21
58	Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test. Life Sciences, 2015, 120, 8-12.	4.3	20
59	Endogenous neuropeptide S tone influences sleep–wake rhythm in rats. Neuroscience Letters, 2014, 581, 94-97.	2.1	17
60	A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. Bioorganic and Medicinal Chemistry, 2014, 22, 3703-3712.	3.0	32
61	Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. Behavioural Brain Research, 2014, 266, 29-36.	2.2	19
62	Pharmacological characterization of tachykinin tetrabranched derivatives. British Journal of Pharmacology, 2014, 171, 4125-4137.	5.4	15
63	Internalization and Stability of a Thymidylate Synthase Peptide Inhibitor in Ovarian Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 10551-10556.	6.4	10
64	Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2014, 57, 1355-1367.	6.4	22
65	Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides. Journal of Proteome Research, 2014, 13, 5250-5261.	3.7	22
66	N-Carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide Enhances Staurosporine Cytotoxic Effects Likely Inhibiting the Protective Action of Magmas toward Cell Apoptosis. Journal of Medicinal Chemistry, 2014, 57, 4606-4614.	6.4	3
67	Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P. Applied Radiation and Isotopes, 2014, 92, 25-31.	1.5	25
68	Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. Psychopharmacology, 2013, 226, 347-355.	3.1	33
69	Ligands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 23964-23978.	3.4	22
70	Unexpected impact of the number of glutamine residues on metal complex stability. Metallomics, 2013, 5, 214.	2.4	33
71	Medicinal Chemistry, Pharmacology, and Biological Actions of Peptide Ligands Selective for the Nociceptin/Orphanin FQ Receptor. ACS Symposium Series, 2013, , 275-325.	0.5	18
72	Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. Journal of Neurophysiology, 2013, 110, 1765-1781.	1.8	55

#	Article	IF	CITATIONS
73	Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 304, L657-L664.	2.9	22
74	Nociceptin/Orphanin FQ., 2013, , 1577-1585.		4
75	The Nociceptin/Orphanin FQ Receptor Antagonist UFP-101 Reduces Microvascular Inflammation to Lipopolysaccharide In Vivo. PLoS ONE, 2013, 8, e74943.	2.5	12
76	Mixed Tridentate & Spanner and Monodentate & Spanner and Ligands as Chelating Systems for Rhenium-188 and Technetium-99m Nitrido Radiopharmaceuticals. Current Radiopharmaceuticals, 2013, 6, 137-145.	0.8	18
77	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
78	Anxiolytic―and panicolyticâ€like effects of Neuropeptide S in the mouse elevated T―maze. European Journal of Neuroscience, 2012, 36, 3531-3537.	2.6	40
79	Thermodynamic and spectroscopic investigation on the role of Met residues in Cull binding to the non-octarepeat site of the human prion protein. Metallomics, 2012, 4, 794.	2.4	22
80	Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. Pharmacology Biochemistry and Behavior, 2012, 103, 197-203.	2.9	16
81	Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature, 2012, 485, 395-399.	27.8	430
82	The Coordination of Ni ^{II} and Cu ^{II} lons to the Polyhistidyl Motif of Hpn Protein: Is It as Strong as We Think?. Chemistry - A European Journal, 2012, 18, 11088-11099.	3.3	28
83	Synthesis and Separation of the Enantiomers of the Neuropeptide S Receptor Antagonist (9 <i>R</i> / <i>S</i> /o>3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4- <i>a</i>]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68). Journal of Medicinal Chemistry, 2011, 54, 2738-2744.	6.4	21
84	Neuropeptide S inhibits stress-stimulated faecal output in the rat. Pharmacological Research, 2011, 64, 471-477.	7.1	10
85	Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. Life Sciences, 2011, 89, 735-740.	4.3	6
86	Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat. Peptides, 2011, 32, 44-50.	2.4	23
87	UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Neuroscience and Therapeutics, 2011, 17, 178-198.	3.9	36
88	Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice. Pharmacology Biochemistry and Behavior, 2011, 99, 726-730.	2.9	13
89	Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E542-9.	7.1	77
90	Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 153-160.	3.0	20

#	Article	IF	CITATIONS
91	Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 193-199.	3.0	3
92	Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain, 2010, 148, 107-113.	4.2	70
93	Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Medicinal Research Reviews, 2010, 30, 751-777.	10.5	89
94	<i>In vitro</i> activity of dermaseptin S1 derivatives against genital pathogens. Apmis, 2010, 118, 674-680.	2.0	22
95	Nociceptin Modulates Bronchoconstriction Induced by Sensory Nerve Activation in Mouse Lung. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 250-254.	2.9	35
96	Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides, 2010, 31, 915-925.	2.4	53
97	In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 549-555.	2.5	55
98	Nociceptin/Orphanin FQ Modulates Motor Behavior and Primary Motor Cortex Output Through Receptors Located in Substantia Nigra Reticulata. Neuropsychopharmacology, 2009, 34, 341-355.	5.4	22
99	Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. European Journal of Pharmacology, 2009, 614, 50-57.	3.5	33
100	Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 599-607.	3.0	59
101	Desensitisation of native and recombinant human urotensin-II receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 380, 451-457.	3.0	6
102	Chronic treatment with the selective NOP receptor antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology, 2009, 207, 173-189.	3.1	66
103	The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. European Journal of Neuroscience, 2009, 30, 1594-1602.	2.6	38
104	Structure $\hat{a}\in \hat{a}$ ctivity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H), $4\hat{a}\in \hat{a}$ -piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. Bioorganic and Medicinal Chemistry, 2009, 17, 5080-5095.	3.0	27
105	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 524-529.	6.4	53
106	Further Studies at Neuropeptide S Position 5: Discovery of Novel Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 4068-4071.	6.4	24
107	The hypothalamus–pituitary–adrenal axis does not influence the protective effects of nociceptin/orphanin FQ on the rat gastric mucosa. Regulatory Peptides, 2009, 154, 32-38.	1.9	3
108	Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides, 2009, 30, 248-255.	2.4	9

#	Article	IF	Citations
109	Structure–activity relationship study on Tyr9 of urotensin-II(4–11): Identification of a partial agonist of the UT receptor. Peptides, 2009, 30, 1130-1136.	2.4	9
110	The complex-formation behaviour of His residues in the fifth Cu2+ binding site of human prion protein: a close look. New Journal of Chemistry, 2009, 33, 2300.	2.8	23
111	The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Medicine, 2008, 34, 2284-2290.	8.2	46
112	Binding of the novel radioligand [3H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 553-561.	3.0	21
113	Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorganic and Medicinal Chemistry, 2008, 16, 8205-8209.	3.0	44
114	Structure–activity study at positions 3 and 4 of human neuropeptide S. Bioorganic and Medicinal Chemistry, 2008, 16, 8841-8845.	3.0	15
115	Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic ⟨i>N⟨/i>â€formyl tripeptide forâ€Metâ€Leuâ€Pheâ€OH. FEBS Journal, 2008, 275, 449-457.	4.7	5
116	Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices. European Journal of Pharmacology, 2008, 579, 110-115.	3.5	5
117	Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. Neuroscience Letters, 2008, 440, 275-279.	2.1	14
118	Structure–activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides, 2008, 29, 674-679.	2.4	2
119	Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides, 2008, 29, 93-103.	2.4	75
120	GABAA signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze. Peptides, 2008, 29, 1404-1412.	2.4	14
121	Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides, 2008, 29, 2286-2291.	2.4	88
122	Cull binding sites located at His-96 and His-111 of the human prion protein: thermodynamic and spectroscopic studies on model peptides. Dalton Transactions, 2008, , 5207.	3.3	49
123	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 2. Journal of Medicinal Chemistry, 2008, 51, 655-658.	6.4	25
124	Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2977-H2985.	3.2	33
125	UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: Behavioral and electrophysiological studies in mice. Peptides, 2007, 28, 663-669.	2.4	29
126	In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides, 2007, 28, 1240-1251.	2.4	72

#	Article	IF	CITATIONS
127	Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. Peptides, 2007, 28, 1572-1579.	2.4	17
128	Conformationâ^'Activity Relationship of Neuropeptide S and Some Structural Mutants:Â Helicity Affects Their Interaction with the Receptor. Journal of Medicinal Chemistry, 2007, 50, 4501-4508.	6.4	21
129	Structural and Dynamic Characterization of Copper(II) Binding of the Human Prion Protein Outside the Octarepeat Region. Chemistry - A European Journal, 2007, 13, 1991-2001.	3.3	60
130	Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with $\hat{Cl}_{\pm},\hat{l}_{\pm}$ -dialkylated amino acids. Bioorganic and Medicinal Chemistry, 2007, 15, 4434-4443.	3.0	51
131	Daily Intravesical Instillation of 1 mg Nociceptin/Orphanin FQ for the Control of Neurogenic Detrusor Overactivity: A Multicenter, Placebo Controlled, Randomized Exploratory Study. Journal of Urology, 2006, 176, 2098-2102.	0.4	34
132	Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences. Pain, 2006, 124, 100-108.	4.2	60
133	Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats. Peptides, 2006, 27, 2803-2810.	2.4	13
134	In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,D Trp7,Dab8] urotensin II(4-11) (UFP-803). British Journal of Pharmacology, 2006, 147, 92-100.	5.4	30
135	Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorganic and Medicinal Chemistry, 2006, 14, 692-704.	3.0	34
136	New approaches to high-throughput structure characterization of SH3 complexes: The example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae. Protein Science, 2006, 15, 795-807.	7.6	14
137	Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 148-157.	3.0	21
138	In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. European Journal of Pharmacology, 2006, 539, 39-48.	3.5	24
139	The $\hat{l}\pm$ -to- \hat{l}^2 Conformational Transition of Alzheimer's A \hat{l}^2 -(1-42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of \hat{l}^2 Conformation Seeding. ChemBioChem, 2006, 7, 257-267.	2.6	375
140	Structure-Activity Studies on Neuropeptide S. Journal of Biological Chemistry, 2006, 281, 20809-20816.	3.4	89
141	Modeling of overloaded gradient elution of nociceptin/orphanin FQ in reversed-phase liquid chromatography. Journal of Chromatography A, 2005, 1079, 162-172.	3.7	26
142	Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. British Journal of Pharmacology, 2005, 144, 813-820.	5 . 4	32
143	[Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray. European Journal of Pharmacology, 2005, 515, 47-53.	3 . 5	14
144	The Interaction of Highly Helical Structural Mutants with the NOP Receptor Discloses the Role of the Address Domain of Nociceptin/Orphanin FQ. Chemistry - A European Journal, 2005, 11, 2061-2070.	3.3	17

#	Article	IF	Citations
145	Structure-activity relationship study on human urotensin II. Journal of Peptide Science, 2005, 11, 85-90.	1.4	34
146	Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease. Journal of Neuroscience, 2005, 25, 9591-9601.	3.6	116
147	Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 643-651.	2.5	31
148	Peripheral Mechanisms Involved in Gastric Mucosal Protection by Intracerebroventricular and Intraperitoneal Nociceptin in Rats. Endocrinology, 2005, 146, 3861-3867.	2.8	23
149	[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1114-1123.	2.5	36
150	Copper-ion interaction with the 106–113 domain of the prion protein: a solution-equilibria study on model peptides. Dalton Transactions, 2005, , 2876.	3.3	24
151	N- and C-Terminal Modifications of Nociceptin/Orphanin FQ Generate Highly Potent NOP Receptor Ligands. Journal of Medicinal Chemistry, 2005, 48, 1421-1427.	6.4	25
152	Conversion of the Potent δ-Opioid Agonist H-Dmt-Tic-NH-CH2-Bid into δ-Opioid Antagonists by N-Benzimidazole Alkylation1. Journal of Medicinal Chemistry, 2005, 48, 8112-8114.	6.4	15
153	Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation. Peptides, 2005, 26, 1492-1496.	2.4	17
154	Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat. Regulatory Peptides, 2005, 124, 203-207.	1.9	21
155	UFPâ€101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Neuroscience & Therapeutics, 2005, 11, 97-112.	4.0	88
156	Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior. Journal of Neuroscience, 2004, 24, 6659-6666.	3.6	109
157	RAPID COMMUNICATION: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. Journal of Neurochemistry, 2004, 91, 1501-1504.	3.9	44
158	Solution Structure of ZASP PDZ Domain. Structure, 2004, 12, 611-622.	3.3	45
159	Urantide mimics urotensin-Il induced calcium release in cells expressing recombinant UT receptors. European Journal of Pharmacology, 2004, 498, 83-86.	3.5	53
160	Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes. Brain Research, 2004, 1003, 18-25.	2.2	7
161	Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 347-352.	3.0	17
162	Copper Binding to the Neurotoxic Peptide PrP106-126: Thermodynamic and Structural Studies. ChemBioChem, 2004, 5, 349-359.	2.6	63

#	Article	IF	CITATIONS
163	Direct Influence of C-Terminally Substituted Amino Acids in the Dmtâ^'Tic Pharmacophore on Î-Opioid Receptor Selectivity and Antagonism. Journal of Medicinal Chemistry, 2004, 47, 4066-4071.	6.4	19
164	Solution Structure of Amyloid \hat{l}^2 -Peptide (25 \hat{a}^3 35) in Different Media. Journal of Medicinal Chemistry, 2004, 47, 4231-4238.	6.4	117
165	Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Letters, 2004, 577, 284-288.	2.8	17
166	Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. Peptides, 2004, 25, 1013-1020.	2.4	30
167	Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 342-347.	3.0	33
168	Synthesis and opioid activity of N,N-Dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: acquisition of potent δ antagonism. Bioorganic and Medicinal Chemistry, 2003, 11, 5435-5441.	3.0	19
169	Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. British Journal of Pharmacology, 2003, 138, 91-98.	5.4	57
170	Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. British Journal of Pharmacology, 2003, 139, 21-27.	5.4	12
171	Nociceptin/Orphanin FQ(1–13)NH2 analogues modified in the Phe1-Gly2 peptide bond. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 365-368.	2.2	14
172	Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology, 2003, 61, 946-950.	1.0	45
173	Characterization of Nociceptin/Orphanin FQ Binding Sites in Dog Brain Membranes. Anesthesia and Analgesia, 2003, 97, 741-747.	2.2	4
174	[Arg14,Lys15]Nociceptin, a Highly Potent Agonist of the Nociceptin/Orphanin FQ Receptor: in Vitro and in Vivo Studies. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 57-63.	2.5	52
175	Evaluation of the Dmtâ^'Tic Pharmacophore:Â Conversion of a Potent Î-Opioid Receptor Antagonist into a Potent Î Agonist and Ligands with Mixed Properties. Journal of Medicinal Chemistry, 2002, 45, 713-720.	6.4	93
176	Potent δ-Opioid Receptor Agonists Containing the Dmtâ^'Tic Pharmacophore. Journal of Medicinal Chemistry, 2002, 45, 5556-5563.	6.4	85
177	The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation. Journal of Molecular Biology, 2002, 316, 305-315.	4.2	22
178	Crystal Structures of Dipeptides Containing the Dmt-Tic Pharmacophore. Journal of Medicinal Chemistry, 2002, 45, 5506-5513.	6.4	14
179	Intrathecal [Nphe1]nociceptin(1-13)NH2 selectively reduces the spinal inhibitory effect of nociceptin. Life Sciences, 2002, 70, 1151-1157.	4.3	11
180	[Nphe1]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices. Neuropharmacology, 2002, 42, 246-252.	4.1	20

#	Article	IF	CITATIONS
181	Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides, 2002, 23, 117-125.	2.4	44
182	Effects of [(pF)Phe4]nociceptin/orphanin FQ-(1–13)NH2 on GTPγ35S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. European Journal of Pharmacology, 2002, 443, 7-12.	3.5	16
183	Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors. European Journal of Pharmacology, 2002, 449, 17-22.	3.5	8
184	Pharmacological characterisation of [(pX)Phe 4]nociceptin(1-13)amide analogues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 442-449.	3.0	29
185	Pharmacological characterisation of [(pX)Phe 4]nociceptin(1-13)NH 2 analogues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 450-456.	3.0	27
186	Solution structure of the Alzheimer amyloid βâ€peptide (1–42) in an apolar microenvironment. FEBS Journal, 2002, 269, 5642-5648.	0.2	577
187	Pharmacological Profile Of Nociceptin/Orphanin Fq Receptors. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 223-228.	1.9	58
188	Solution structure of nociceptin peptides. Journal of Peptide Science, 2002, 8, 497-509.	1.4	12
189	[Nphe ¹ ,Arg ¹⁴ ,Lys ¹⁵]Nociceptinâ€NH ₂ , a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. British Journal of Pharmacology, 2002, 136, 303-311.	5 . 4	158
190	Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. British Journal of Pharmacology, 2002, 136, 764-772.	5 . 4	59
191	A new ligand for the urotensin II receptor. British Journal of Pharmacology, 2002, 137, 311-314.	5.4	53
192	Generation of New Dint-Tic δOpioid Antagonists: N-Alkylation. , 2002, , 603-604.		0
193	Synthesis and pharmacological activity of a new antagonist of the OP4 receptor. , 2002, , 227-228.		0
194	Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 199-210.	2.4	45
195	Effects of nociceptinNH2 and [Nphe1]nociceptin(1–13)NH2 on rat brain noradrenaline release in vivo and in vitro. Neuroscience Letters, 2001, 303, 173-176.	2.1	23
196	Studies on the antinociceptive effect of [Nphe1]nociceptin($1\hat{a}\in 13$)NH2 in mice. Neuroscience Letters, 2001, 316, 25-28.	2.1	30
197	URODYNAMIC AND CLINICAL EVIDENCE OF ACUTE INHIBITORY EFFECTS OF INTRAVESICAL NOCICEPTIN/ORPHANIN FQ ON DETRUSOR OVERACTIVITY IN HUMANS: A PILOT STUDY. Journal of Urology, 2001, 166, 2237-2240.	0.4	43
198	Structureâ°'Activity Studies of the Phe4Residue of Nociceptin(1â°'13)-NH2:Â Identification of Highly Potent Agonists of the Nociceptin/Orphanin FQ Receptor. Journal of Medicinal Chemistry, 2001, 44, 3956-3964.	6.4	41

#	Article	IF	Citations
199	Endogenous nociceptin signaling and stress-induced analgesia. NeuroReport, 2001, 12, 3009-3013.	1.2	39
200	Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 161-165.	3.0	53
201	Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 551-555.	3.0	43
202	Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens. British Journal of Clinical Pharmacology, 2001, 51, 355-358.	2.4	11
203	Immunosensing by a Synthetic Ligand-Gated Ion Channel. Angewandte Chemie - International Edition, 2001, 40, 1740-1743.	13.8	57
204	Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent \hat{l} -opioid antagonist. Brain Research, 2001, 902, 131-134.	2.2	11
205	Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. Journal of Clinical Investigation, 2001, 107, 457-466.	8.2	73
206	Computational Chemistry and Opioidmimetics: Receptor-Ligand Interactions of Dmt-Tic Peptides. , 2001, , 851-852.		0
207	URODYNAMIC AND CLINICAL EVIDENCE OF ACUTE INHIBITORY EFFECTS OF INTRAVESICAL NOCICEPTIN/ORPHANIN FQ ON DETRUSOR OVERACTIVITY IN HUMANS:. Journal of Urology, 2001, , 2237-2240.	0.4	1
208	Identification of a novel 45ÂkDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. Biochemical Journal, 2000, 351, 537.	3.7	9
209	Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. Biochemical Journal, 2000, 351, 537-543.	3.7	30
210	The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. NeuroReport, 2000, 11, 2369-2372.	1.2	40
211	Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist. NeuroReport, 2000, 11, 2083-2086.	1.2	2
212	Solution structure of nocistatin, a new peptide analgesic. Biopolymers, 2000, 53, 257-264.	2.4	7
213	Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2745-2748.	2.2	22
214	Characterization of [Nphe1] nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist. British Journal of Pharmacology, 2000, 129, 1183-1193.	5.4	178
215	Pharmacology of nociceptin and its receptor: a novel therapeutic target. British Journal of Pharmacology, 2000, 129, 1261-1283.	5.4	395
216	[Nphe1]nociceptin-(1–13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum. European Journal of Pharmacology, 2000, 397, 383-388.	3. 5	15

#	Article	IF	CITATIONS
217	Inverse agonism by Dmt–Tic analogues and HS 378, a naltrindole analogue. European Journal of Pharmacology, 2000, 406, R1-R3.	3.5	28
218	Further Studies on Nociceptin-Related Peptides:Â Discovery of a New Chemical Template with Antagonist Activity on the Nociceptin Receptor. Journal of Medicinal Chemistry, 2000, 43, 2805-2813.	6.4	68
219	Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. Peptides, 2000, 21, 923-933.	2.4	37
220	Nociceptin/orphanin FQ receptor ligands. Peptides, 2000, 21, 935-947.	2.4	96
221	Studies of the cardiovascular effects of nociceptin and related peptides. Peptides, 2000, 21, 985-993.	2.4	22
222	Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship. Peptides, 2000, 21, 1587-1595.	2.4	25
223	Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides, 2000, 21, 1663-1671.	2.4	24
224	Pain peptides. Solution structure of orphanin FQ2. FEBS Letters, 2000, 473, 157-160.	2.8	5
225	Cardiovascular Effects of Nociceptin in Unanesthetized Mice. Hypertension, 1999, 33, 914-919.	2.7	68
226	Comparison of the effects of [Phe1 $\hat{\Gamma}$ (CH2 -NH)Gly2]Nociceptin (1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. British Journal of Pharmacology, 1999, 127, 123-130.	5.4	76
227	Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359, 160-167.	3.0	104
228	[Nphe1]nociceptin-(1–13)-NH2 antagonizes nociceptin effects in the mouse colon. European Journal of Pharmacology, 1999, 385, R3-R5.	3.5	64
229	Structure–activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. Il Farmaco, 1999, 54, 810-825.	0.9	32
230	Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. European Journal of Immunology, 1999, 29, 2579-2589.	2.9	24
231	Further Studies on the Dmt-Tic Pharmacophore: Hydrophobic Substituents at the C-Terminus Endow δ Antagonists To Manifest μ Agonism or μ Antagonism. Journal of Medicinal Chemistry, 1999, 42, 5010-5019.	6.4	71
232	Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sciences, 1999, 64, PL157-PL163.	4.3	27
233	Supraspinal and spinal effects of [Phe1Î ⁻ (CH2-NH)Gly2]-nociceptin(1–13)-NH2 on nociception in the rat. Life Sciences, 1999, 66, 257-264.	4.3	22
234	Nociceptin Binding Sites in Frog (Rana esculenta) Brain Membranes. Biochemical and Biophysical Research Communications, 1999, 260, 592-596.	2.1	16

#	Article	IF	CITATIONS
235	A new selective antagonist of the nociceptin receptor. British Journal of Pharmacology, 1998, 123, 163-165.	5.4	221
236	Rational design of dynorphin A analogues with \hat{l} -receptor selectivity and antagonism for \hat{l} - and \hat{l} -receptors. Bioorganic and Medicinal Chemistry, 1998, 6, 57-62.	3.0	26
237	Design of $\hat{\Gamma}$ -opioid peptide antagonists for emerging drug applications. Drug Discovery Today, 1998, 3, 284-294.	6.4	40
238	High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Letters, 1998, 421, 95-99.	2.8	12
239	Ultraselective antagonists of the d-opioid receptor. Expert Opinion on Therapeutic Targets, 1998, 2, 45-47.	1.0	0
240	Structureâ^'Activity Study of the Nociceptin(1â^'13)-NH2N-Terminal Tetrapeptide and Discovery of a Nociceptin Receptor Antagonist. Journal of Medicinal Chemistry, 1998, 41, 3360-3366.	6.4	81
241	Opioid Diketopiperazines: Refinement of the $\hat{\Gamma}$ Opioid Antagonist Pharmacophore. Biological Chemistry, 1997, 378, 107-114.	2.5	29
242	Opioid Diketopiperazines: Synthesis and Activity of a Prototypic Class of Opioid Antagonists. Biological Chemistry, 1997, 378, 19-29.	2.5	41
243	Address and Message Sequences for the Nociceptin Receptor:  A Structureâ^'Activity Study of Nociceptin-(1â^'13)-peptide amide. Journal of Medicinal Chemistry, 1997, 40, 1789-1793.	6.4	224
244	Helix-Inducing \hat{l}_{\pm} -Aminoisobutyric Acid in Opioid Mimetic Deltorphin C Analogues. Journal of Medicinal Chemistry, 1997, 40, 2579-2587.	6.4	22
245	Evolution of the Dmt-Tic Pharmacophore: N-Terminal Methylated Derivatives with Extraordinary δ Opioid Antagonist Activity. Journal of Medicinal Chemistry, 1997, 40, 3100-3108.	6.4	85
246	Synthesis and Pharmacological Activity of Deltorphin and Dermorphin-Related Glycopeptides. Journal of Medicinal Chemistry, 1997, 40, 2948-2952.	6.4	58
247	Design and Solution Structure of a Partially Rigid Opioid Antagonist Lacking the Basic Center - Models of Antagonism. FEBS Journal, 1997, 247, 66-73.	0.2	24
248	Dmt-Tic-OH, a highly selective and potent $\hat{\Gamma}$ -opioid dipeptide receptor antagonist after systemic administration in the mouse. Life Sciences, 1996, 59, PL93-PL98.	4.3	23
249	Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B. European Journal of Pharmacology, 1996, 302, 37-42.	3.5	41
250	The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. European Journal of Pharmacology, 1996, 311, R3-R5.	3.5	122
251	Design and Synthesis of 1-Aminocycloalkane-1-carboxylic Acid-Substituted Deltorphin Analogues:Â Unique δand μ Opioid Activity in Modified Peptides. Journal of Medicinal Chemistry, 1996, 39, 773-780.	6.4	30
252	Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. Journal of Leukocyte Biology, 1996, 60, 207-213.	3.3	36

#	ARTICLE	IF	CITATIONS
253	Calmodulin Binding Sites of the Skeletal, Cardiac, and Brain Ryanodine Receptor Ca2+ Channels: Modulation by the Catalytic Subunit of cAMP-Dependent Protein Kinase?. Biochemistry, 1995, 34, 5120-5129.	2.5	41
254	Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinolineâ€3 arboxylic acid at position 2. International Journal of Peptide and Protein Research, 1995, 45, 567-573.	0.1	21
255	l´Opioidmimetic Antagonists: Prototypes for Designing a New Generation of Ultraselective Opioid Peptides. Molecular Medicine, 1995, 1, 678-689.	4.4	116
256	Conformationally constrained amino acids: A concise route to a methionine analogue. Tetrahedron, 1994, 50, 12973-12978.	1.9	6
257	Conversion of Enkephalin and Dermorphin into delta-Selective Opioid Antagonists by Single-Residue Substitution. FEBS Journal, 1994, 224, 241-247.	0.2	48
258	Synthesis and pharmacological activity of the <i>N</i> â€ŧerminal dermorphin tetrapeptide analogs with CH ₂ â€NH peptide bond isosteres. International Journal of Peptide and Protein Research, 1992, 40, 437-444.	0.1	7
259	Synthesis of spinacine and spinacine derivatives: crystal and molecular structures of Ni€-hydroxymethyl spinacine and Nα-methyl spinaceamine. Journal of Chemical Crystallography, 1991, 27, 507-513.	1.1	8